ReviewFrontiers in immunology2022
Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Extracellular vesicles in osteosarcoma: bridging resistance, immunity, and clinical translation.Journal of bone oncology · 2026Review
- Bioorthogonal Click Chemistry-Enabled Enrichment of Extracellular Vesicles for Integrated Molecular and Functional Liquid Biopsy§.Accounts of chemical research · 2026Article
- Emerging research themes in drug resistance in osteosarcoma: a 25-year bibliometric and visualized analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- SLC7A5 serves as a potential therapeutic target for osteosarcoma: a comprehensive analysis based on bioinformatics and experimental validation.American journal of cancer research · 2026Article
- Extracellular Vesicles in Osteosarcoma: Mechanisms, Diagnostics and Therapeutic Applications.Drug design, development and therapy · 2026Review
- Tenascin-C-enriched extracellular vesicles contribute to osteosarcoma progression via regulation of the angiotensin II receptor type 1 pathway.Journal of molecular histology · 2025Article
- Noninvasive Assessment of Protease Activity in Osteosarcoma via Click Chemistry-Mediated Enrichment of Extracellular Vesicles.Advanced functional materials · 2025Article
- Explore the potential mechanism of Huachansu injection against osteosarcoma via metabolomics, network pharmacology and bioinformatics.Chinese medicine · 2025Article
- Osteosarcoma cell-derived CCL2 facilitates lung metastasis via accumulation of tumor-associated macrophages.Cancer immunology, immunotherapy : CII · 2025Article
- Upregulated ATG4B predicts poor prognosis and correlates with angiogenesis in osteosarcoma.Journal of the Egyptian National Cancer Institute · 2025Article
- MAPK-targeted therapies in non-gastrointestinal stromal tumor soft tissue sarcomas: current landscape and future directions.Frontiers in oncology · 2025Review
- Exosome-transmitted circular RNA circ-LMO7 facilitates the progression of osteosarcoma by regulating miR-21-5p/ARHGAP24 axis.Cancer biology & therapy · 2024Article
- Article
- Extracellular Vesicles from a Novel Chordoma Cell Line, ARF-8, Promote Tumorigenic Microenvironmental Changes When Incubated with the Parental Cells and with Human Osteoblasts.International journal of molecular sciences · 2024Article
- Evaluating Circulating Biomarkers for Diagnosis, Prognosis, and Tumor Monitoring in Pediatric Sarcomas: Recent Advances and Future Directions.Biomolecules · 2024Review
- The role of cancer-associated fibroblasts and exosomal miRNAs-mediated intercellular communication in the tumor microenvironment and the biology of carcinogenesis: a systematic review.Cell death discovery · 2024Review
- IRF5 suppresses metastasis through the regulation of tumor-derived extracellular vesicles and pre-metastatic niche formation.Scientific reports · 2024Article
- Directional Endothelial Communication by Polarized Extracellular Vesicle Release.Circulation research · 2024Article
- The emerging applications and advancements of Raman spectroscopy in pediatric cancers.Frontiers in oncology · 2023Review
- Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is a primary bone cancer that is highly prevalent among adolescents and adults below the age of 20 years. The prognostic outcome of metastatic OS or relapse is extremely poor; thus, developing new diagnostic and therapeutic strategies for treating OS is necessary. Extracellular vesicles (EVs) ranging from 30-150 nm in diameter are commonly produced in different cells and are found in various types of body fluids. EVs are rich in biologically active components like proteins, lipids, and nucleic acids. They also strongly affect pathophysiological processes by modulating the intercellular signaling pathways and the exchange of biomolecules. Many studies have found that EVs influence the occurrence, development, and metastasis of osteosarcoma. The regulation of inflammatory communication pathways by EVs affects OS and other bone-related pathological conditions, such as osteoarthritis and rheumatoid arthritis. In this study, we reviewed the latest findings related to diagnosis, prognosis prediction, and the development of treatment strategies for OS from the perspective of EVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.